Takeda/Lilly underwrite US Rx cost/benefit report

18 October 2001

Eli Lilly and Takeda Pharmaceuticals North America Inc have underwrittenthe 2001 Prescription Drug Benefit Cost and Plan Design Survey report, an annual publication, which they say is well-regarded by health care providers for its information about prescription drug benefit trends and issues. Findings of the survey, conducted by the Pharmacy Benefit Management Institute, were due to be presented at the Academy of Managed Care Pharmacy's annual meeting in Dallas, USA, as this story went to press.

Takeda PNAI's director of national accounts, Michael Gannon, commented: "relationships with health care leaders are very important us, and to our partner Eli Lilly...we welcome the chance to help foster sharing of information about what's working and what's not working in the pharmacy benefits industry so as to help ensure that employers can offer the best benefit to their employees."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

Companies featured in this story

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.